Tg 511-15-01: A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

January 08, 2018
https://clinicaltrials.gov/ct2/show/NCT02414165
Cancer - Brain
Principal Investigator: Tobias Walbert, MD
Recurrent GBM, Anaplastic astrocytoma, brain cancer, recurrent glioblastoma, brain cancer surgery, surgery
Accepting Participants